Skip to Content
Merck
All Photos(3)

Key Documents

View All Documentation

159891

Sigma-Aldrich

3-Methoxybenzylamine

98%

Sign Into View Organizational & Contract Pricing
All Photos(3)

About This Item

Linear Formula:
CH3OC6H4CH2NH2
CAS Number:
5071-96-5
Molecular Weight:
137.18
Beilstein:
1447182
EC Number:
225-779-6
MDL number:
MFCD00008115
UNSPSC Code:
12352100
PubChem Substance ID:
24849839
NACRES:
NA.22

Quality Level

100

Assay

98%

refractive index

n20/D 1.547 (lit.)

bp

140 °C/37 mmHg (lit.)

density

1.072 g/mL at 25 °C (lit.)

functional group

amine

SMILES string

COc1cccc(CN)c1

InChI

1S/C8H11NO/c1-10-8-4-2-3-7(5-8)6-9/h2-5H,6,9H2,1H3

InChI key

GRRIMVWABNHKBX-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

3-Methoxybenzylamine was used in the preparation of 6-substituted purines.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

8A - Combustible corrosive hazardous materials

WGK

WGK 3

Flash Point(F)

235.4 °F - closed cup

Flash Point(C)

113 °C - closed cup

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCK5471
MKBZ2250V
MKBV4913V
MKBT3620V
MKBQ8288V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marek Zatloukal et al.
European journal of medicinal chemistry, 61, 61-72 (2012-07-10)
Several inhibitors of cyclin-dependent kinases (CDKs), including the 2,6,9-trisubstituted purine derivative roscovitine, are currently being evaluated in clinical trials as potential anticancer drugs. Here, we describe a new series of roscovitine derivatives that show increased potency in vitro. The series

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service